ARTHUR D. FLANAGAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The editorial note entitled "Anti-inflammatory and Antirheumatic Drugs" (1) cites Dresner (2) as the source for the statement, "At present the odds seem high against its [meclofenamate sodium] getting acclaim for long-term treatment of rheumatoid arthritis or osteoarthritis." This is an incorrect implication from the Dresner article which simply reported on four multicenter studies of short, 4- to 8-week, duration. These studies were actually extended, and in excess of 500 patients received the drug for periods longer than 12 months after completing the double-blind portion of the investigation reported by Dresner.
The long-term data, although not included
FLANAGAN AD. Correction: Citation of Paper by Dresner. Ann Intern Med. ;95:246. doi: 10.7326/0003-4819-95-2-246_2
Download citation file:
Published: Ann Intern Med. 1981;95(2):246.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use